跳至主要内容
临床试验/RPCEC00000309
RPCEC00000309已完成1 期

Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19

Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico.0 个研究点目标入组 200 人开始时间: 2020年5月5日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
18 years. 至 75 years.(—)
性别
All

入选标准

  • A) For outpatients treated at home (without pneumonia and with peripheral blood oxygen saturation equal to or greater than 90% breathing ambient air):
  • 1. Patients diagnosed with COVID-19, with uncomplicated disease.
  • 2. Age: 18 years - 75 years old.
  • 3. Acceptance in writing, with prior information.
  • B) For hospitalized patients (with pneumonia or peripheral blood oxygen saturation less than 90% breathing ambient air or requiring mechanical ventilation):
  • 1. Patients diagnosed with COVID-19, with mild or severe pneumonia hospitalized.
  • 2. Age: 18 years - 75 years old.
  • 3. Acceptance in writing, with prior information.

排除标准

  • FOR ALL PATIENTS
  • 1. Rheumatoid arthritis.
  • 2. Autoimmune diseases.
  • 3. Previously diagnosed cardiac diseases (ischemic).
  • 4. Chronic decompensated systemic disease prior to the diagnosis of COVID-19.
  • 5. Creatinine 1.25 times higher than the normal value or creatinine clearance less than 50 milliliters / minute (Cockfrot and Gault method), prior to the diagnosis of COVID-19.
  • 6. Blood hemoglobin less than 10g / Dl, prior to the diagnosis of COVID-19.
  • 7. Increase in the last month of diastolic blood pressure to 110 mmHg or more and / or appearance of hematuria or proteinuria greater than 300 milligrams / day.
  • 8. Intestinal pseudo-obstruction. Defined as abdominal pain, with airborne levels on radiographs of the AP abdomen and lateral foot.
  • 9. Pregnant and lactating women.
  • 10. Drug addiction (illicit drugs).
  • 11. Known liver disease prior to the diagnosis of COVID-19 with a doubling of liver function tests (Aspartatoamine transferase (AST), Alaninoamine transferase (ALT), Alkaline phosphatase, Bilirubins).
  • 12. Presence of Cancer.
  • 13. Other pathologies at the discretion of the researcher.

研究者

发起方
Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico.

相似试验

Therapy for COVID-19-Phase I-II | 临床试验